029 Group SE

Earnings Release • Jan 17, 2003

News Details

Ad-hoc | 17 January 2003 20:20

Rhein Biotech N.V. english

Rhein Biotech 2002 sales and profit updated Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Maastricht, 17th January 2003 Rhein Biotech announced today that it will not reach its earlier forecasted sales and profit targets for the year 2002. Sales were affected by the decision of Rhein Biotech to step out of the trade goods business in Korea as of October 1, 2002 as well as a weak dollar exchange rate. A delay in Hepatitis B tender sales from December 2002, to the beginning of 2003 further affected the sales in 2002, leading to a total turnover of around EUR 73 million. The gross margin on products sales has remained stable compared to 2001. Rhein Biotech expects to reach a net income in the range of EUR 2-3 million excluding acquisition and restructuring costs. The final results including any possible goodwill impairment as well as acquisition and restructuring costs cannot be further specified at this moment. Rhein Biotech’s 2002 annual results will be published on March 25. Furthermore Rhein Biotech announces that Dr. Jo resigned from the supervisory board of Rhein Biotech N.V. Dr. Jo is currently a member of the Berna Biotech board. end of ad-hoc-announcement (c)DGAP 17.01.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Rhein Biotech is now a member of the Berna Biotech Group, a leading player for innovation in vaccines. For further information Rhein Biotech N.V. Company Contact: Marcel Jacobs Communication Manager E: m.jacobs@rheinbiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt; Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München und Stuttgart 172020 Jän 03